Table 2 Averaged relative volumes of GTVs covered by 95% of prescription dose ( GV 95 ) for different planning strategies
From: Evaluation and comparison of New 4DCT based strategies for proton treatment planning for lung tumors
| Â | Case | A | B | C | D | E | F | G | H | I | J | K | L | MGV 95 | STDGV 95 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GV 95 (%) | CVCT plan | 64.9 | 84.1 | 97.5 | 99.8 | 97.3 | 95.1 | 93.8 | 97.0 | 99.9 | 99.8 | 100 | 98.4 | 94.1 | 10.2 |
MIP3 plan | 82.2 | 88.3 | 97.1 | 100 | 96.9 | 100 | 96.3 | 100 | 100 | 99.8 | 99.7 | 100 | 96.7 | 5.7 | |
AVG plan | 64.0 | 86.3 | 90.9 | 96.3 | 95.3 | 99.8 | 91.5 | 100 | 100 | 99.7 | 100 | 100 | 93.6 | 10.4 | |
EE plan | 69.1 | 89.7 | 96.3 | 99.8 | 96.5 | 99.9 | 94.4 | 100 | 100 | 99.8 | 100 | 99.8 | 95.4 | 8.9 | |
GM LD (Gy) | CVCT plan | 1.0 | 1.9 | 3.6 | 2.9 | 3.6 | 4.9 | 6.6 | 4.1 | 5.6 | 7.3 | 11.1 | 11.7 | Â | Â |
MIP3 plan | 1.1 | 2.0 | 3.7 | 3.0 | 3.8 | 5.1 | 6.9 | 4.5 | 5.3 | 7.3 | 11.5 | 11.0 | Â | Â | |
AVG plan | 0.9 | 2.0 | 2.9 | 2.5 | 3.4 | 4.1 | 5.5 | 4.0 | 4.5 | 6.2 | 11.3 | 11.0 | Â | Â | |
| Â | EE plan | 0.8 | 2.0 | 3.1 | 2.5 | 3.4 | 4.2 | 5.7 | 3.9 | 4.7 | 6.5 | 11.5 | 11.0 | Â | Â |